• Shanghai Henlius Biotech's board backed revising the HLX01 collaboration annual cap, subject to independent shareholder approval.
• The cap for the year ending Dec. 31, 2026, would rise to RMB 714 million from RMB 682 million.
• Fosun Pharma Industrial Development and its associates, holding 63.22% of issued shares, will abstain from voting at the extraordinary general meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261027-12384845), on October 27, 2026, and is solely responsible for the information contained therein.